[ad_1]
DUBLIN, Oct. 28, 2022 /PRNewswire/ — The “Kidney Cancer Drugs Market, by Therapy, by Pharmacological Class, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.
Clear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells that make up clear cell Renal Cell Carcinoma look very pale or clear. Increasing exposure to cancer risk factors offers lucrative growth outlook in the kidney cancer drugs market, over the forecast period.
According to American Cancer Society’s January 2018 data findings, kidney cancer was among the 10 most common cancers in the US in both men and women. Men had a higher risk of developing kidney cancer, with about 1 in 48 men and 1 in 83 among women facing lifetime risk of developing kidney cancer . Renal cell carcinoma (RCC) was the most common type of kidney cancer among all types of kidney cancer. In addition, according to the same source, around 9 out of 10 kidney cancers were renal cell carcinomas.
Market Dynamics
Key players are engaged in developing cancer immunotherapy drugs to fight cancer and improve immune system. For instance, in January 2019F. Hoffmann-La Roche Ltd., a healthcare company was working on Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A), an engineered monoclonal antibody, that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent ligand 1 cancer immune evasion,…
Full story available on Benzinga.com
[ad_2]
Source link
